Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Innate Immune Engager, Autoimmune, and Myeloid Engager Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FCGR2A (CD32a) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (H131) | FCGR2A (H131) ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View FCGR2A Products |
| Antigen (R131) | FCGR2A (R131) ECD-Fc Fusion Protein Polymorphic variant for genotype-specific screening. High Purity (>95%). Sequence Verified. |
View FCGR2A Products |
| Gene Delivery | FCGR2A Promise-ORF / Lentivirus Full-length ORF for stable macrophage/effector cell lines (ADCP assays). Includes H131/R131 alleles. |
View FCGR2A Products |
| Benchmark Ab | Anti-FCGR2A (Sequence Verified) Recombinant positive control for binding and blocking assays. Theoretical MW confirmed. |
View FCGR2A Products |
| Validator | FCGR2A siRNA Set For knockdown verification in primary cells. Sequence Verified. |
View FCGR2A Products |
| Related Target (Off-target Safety) | FCGR2B (CD32b) Inhibitory counterpart; critical for off-target selectivity screening. High Purity (>95%). |
View FCGR2B Products |
| Related Target (Synergistic) | CD47 Don't eat me signal; combination therapy partner for innate immune activation. |
View CD47 Products |
| Related Target (Family Panel) | FCGR3A (CD16a) F158/V158 High-affinity Fc receptor for comparative binding studies. HEK293 Expressed. |
View FCGR3A Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| H131/R131 Polymorphism Impact on Drug Efficacy | Sequence-verified H131 and R131 allelic variants available with >95% purity for genotype-stratified binding assays. |
| Selectivity vs. Inhibitory FCGR2B | High-purity FCGR2B (CD32b) ortholog protein strictly verified by mass spec for off-target liability screening. |
| ADCP Assay Standardization | Lentivirus particles for robust, stable FCGR2A expression in reporter cell lines. Also provides full-length ORF. |
| Cross-species Cyno/Mouse Evaluation | Human/Cynomolgus FCGR2A ortholog proteins available with matching glycosylation profiles (HEK293 expressed). |
| IgG Subclass Binding Kinetics | Low endotoxin (<1EU/ug) antigens suitable for SPR/BLI studies with IgG1/IgG2/IgG4 immune complexes. |
| Lack of Reliable Controls | Recombinant Benchmark Antibodies included for SPR/BLI standardization; validated siRNA for specificity checks. |
Live FCGR2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FCGR2A therapeutics is intensifying, with major players shifting focus from traditional mAbs and broad immunosuppression to precise Fc receptor modulation. In autoimmune indications such as SLE, lupus nephritis, and ITP, first-generation blocking antibodies have reached Phase II. Concurrently, the next wave of R&D targets myeloid engagers (bispecifics) and allele-selective modulators that discriminate between H131 and R131 polymorphisms. By directly engaging CD32a on macrophages, these approaches aim to overcome the limitations of traditional ADCP while strictly avoiding the inhibitory FCGR2B receptor. Combination therapies with CD47/SIRPα checkpoint inhibitors are also emerging as a key strategy to maximize tumor clearance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking Monoclonal Antibodies | Alexion/AstraZeneca, Takeda, Symphogen | SLE, Lupus Nephritis, ITP | Epitope Mapping & Selectivity Assay (Need H131/R131 variants & FCGR2B counter-screen) |
| Macrophage/Myeloid Engagers (Bispecific) | Innate Pharma, Affimed | Solid Tumors, Lymphoma | Heterodimer Validation (Need High-Purity His-tagged ECD) |
| Fc-Engineered Antibodies | Multiple (industry-wide) | Oncology, Autoimmune | Fc Receptor Binding Kinetics (Need low endotoxin antigens & family panel) |
| Combination Therapies (e.g., +CD47) | Gilead, Trillium | Refractory Malignancies | Selectivity Assay (Need FCGR2B & CD47 counter-screens) |